Cargando…

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors

Background: HER2 exon 20 insertions remain a subset heterogeneous alterations in lung cancer, with currently unmet need for precision targeted therapy. G776delinsVC, a typical HER2 exon 20 deletion-insertion at codon Gly776, was reported to respond discrepantly to afatinib compared with the predomin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Guangjian, Xu, Haiyan, Hu, Jiaqi, Liu, Runze, Hu, Peizeng, Yang, Yaning, Li, Weihua, Hao, Xuezhi, Zhang, Shuyang, Xu, Fei, Ai, Xin, Li, Junling, Wang, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940162/ https://www.ncbi.nlm.nih.gov/pubmed/35330827 http://dx.doi.org/10.3389/fphar.2022.806737

Ejemplares similares

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
por: Xu, Haiyan, et al.
Publicado: (2022)

Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
por: Yang, Yaning, et al.
Publicado: (2023)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
por: Yang, Guangjian, et al.
Publicado: (2022)

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
por: Zhang, Xinyong, et al.
Publicado: (2020)

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
por: Zhang, Shuyang, et al.
Publicado: (2023)

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope
por: Sotiriadou, R, et al.
Publicado: (2001)

HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function
por: Mitani, Yosuke, et al.
Publicado: (2022)

HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan
por: Wang, Bin, et al.
Publicado: (2023)

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
por: Xu, Fei, et al.
Publicado: (2020)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target
por: Shao, Xinyu, et al.
Publicado: (2018)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
por: Li, Kelly, et al.
Publicado: (2023)

Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
por: Zhang, Mai, et al.
Publicado: (2023)

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system
por: KRAWCZYK, PAWEŁ, et al.
Publicado: (2013)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
por: Shan, Jianzhen, et al.
Publicado: (2020)

776 Quality Improvement in Prehospital Burn Care
por: Phillips, Frank, et al.
Publicado: (2022)

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
por: Chen, Kaiyan, et al.
Publicado: (2020)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
por: Xu, Haiyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tvm9fsitsp3tq0mvvar9b9s183